SKB BIO Shares Rise Nearly 3% in Late Trading as Three Studies Selected for Oral Presentation at 2026 ASCO Meeting

Stock News

Apr 24

SKB BIO (06990) saw its shares climb nearly 3% in late trading. At the time of writing, the stock was up 2.24%, trading at HK$475, with a turnover of HK$235 million. The 2026 American Society of Clinical Oncology (ASCO) Annual Meeting is scheduled to take place from May 29 to June 2 in Chicago, USA. According to an announcement on SKB BIO's official social media account, the company will present clinical research results for three assets at the conference: the TROP2 ADC sacituzumab tirumotecan (sac-TMT, marketed as Jiatailai®), the next-generation selective RET inhibitor A400/EP0031 (fumarate form, marketed as Ningtailai®), and the novel ADC SKB500. Full abstracts of the related studies will be published on the official ASCO website on May 21, 2026, local time.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.gotigerhk.com/news/1154953853"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1154953853\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1154953853?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-04-24 15:40","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1154953853","market":"sh","top_or_hot":-1,"title":"SKB BIO Shares Rise Nearly 3% in Late Trading as Three Studies Selected for Oral Presentation at 2026 ASCO Meeting","media":"Stock News","content":"<p>SKB BIO (06990) saw its shares climb nearly 3% in late trading. At the time of writing, the stock was up 2.24%, trading at HK$475, with a turnover of HK$235 million. The 2026 American Society of Clinical Oncology (ASCO) Annual Meeting is scheduled to take place from May 29 to June 2 in Chicago, USA. According to an announcement on SKB BIO's official social media account, the company will present clinical research results for three assets at the conference: the TROP2 ADC sacituzumab tirumotecan (sac-TMT, marketed as Jiatailai®), the next-generation selective RET inhibitor A400/EP0031 (fumarate form, marketed as Ningtailai®), and the novel ADC SKB500. Full abstracts of the related studies will be published on the official ASCO website on May 21, 2026, local time.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>SKB BIO Shares Rise Nearly 3% in Late Trading as Three Studies Selected for Oral Presentation at 2026 ASCO Meeting</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSKB BIO Shares Rise Nearly 3% in Late Trading as Three Studies Selected for Oral Presentation at 2026 ASCO Meeting\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-04-24 15:40</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>SKB BIO (06990) saw its shares climb nearly 3% in late trading. At the time of writing, the stock was up 2.24%, trading at HK$475, with a turnover of HK$235 million. The 2026 American Society of Clinical Oncology (ASCO) Annual Meeting is scheduled to take place from May 29 to June 2 in Chicago, USA. According to an announcement on SKB BIO's official social media account, the company will present clinical research results for three assets at the conference: the TROP2 ADC sacituzumab tirumotecan (sac-TMT, marketed as Jiatailai®), the next-generation selective RET inhibitor A400/EP0031 (fumarate form, marketed as Ningtailai®), and the novel ADC SKB500. Full abstracts of the related studies will be published on the official ASCO website on May 21, 2026, local time.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4588","symbol_name":"碎股","start_time":0,"source_url":"","article_id":"1154953853","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1154953853","pubTimestamp":1777016441,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"SKB BIO (06990) saw its shares climb nearly 3% in late trading. At the time of writing, the stock was up 2.24%, trading at HK$475, with a turnover of HK$235 million. The 2026 American Society of...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4588":"碎股","06990":"科伦博泰生物","VXUS":"国际股票ETF-Vanguard","LU0196878994.USD":"MANULIFE GF CHINA VALUE \"AA\" (USD) INC","BK4585":"ETF&股票定投概念","BK1161":"生物科技"},"translate_title":"SKB BIO股价尾盘上涨近3%，三项研究被选为2026年ASCO会议口头报告","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"VXUS":1,"06990":1},"content_text":"SKB BIO (06990) saw its shares climb nearly 3% in late trading. At the time of writing, the stock was up 2.24%, trading at HK$475, with a turnover of HK$235 million. The 2026 American Society of Clinical Oncology (ASCO) Annual Meeting is scheduled to take place from May 29 to June 2 in Chicago, USA. According to an announcement on SKB BIO's official social media account, the company will present clinical research results for three assets at the conference: the TROP2 ADC sacituzumab tirumotecan (sac-TMT, marketed as Jiatailai®), the next-generation selective RET inhibitor A400/EP0031 (fumarate form, marketed as Ningtailai®), and the novel ADC SKB500. Full abstracts of the related studies will be published on the official ASCO website on May 21, 2026, local time.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}